Human OPC Generation via Olig2 and SHH Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods have been unsuccessful in generating oligodendrocyte precursor cells (OPCs) from human embryonic stem cells (hESCs) using methods similar to those used in mice, and the role of Olig2 transcription in human OPC specification remains uninvestigated, which is crucial for understanding human neural development and promoting remyelination.
Innovation Solution
A method involving the specification of pluripotent stem cells into OPCs through SHH-induced Olig2 expression, with retinoic acid and activators of the SHH pathway, and culturing in specific media conditions to achieve a synchronous population of cells expressing Nkx2.2, Sox10, and PDGFRa, which can differentiate into oligodendrocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If methods similar to those used in mice are applied to generate OPCs from human embryonic stem cells, then the process can be simplified and adapted from existing models, but the methods have been consistently unsuccessful in generating OPCs from human neural stem/progenitor cells
Solution Approach 1:
The invention changes the chemical parameters of the culture medium by specifying exact concentrations of growth factors (FGF2 at 10-100 ng/mL, EGF at 10-100 ng/mL, BDNF at 10-100 ng/mL, GDNF at 10-100 ng/mL) and their combination protocols to successfully generate human OPCs, which differs from mouse methods and achieves reliable human OPC generation
Solution Approach 2:
The differentiation process is segmented into distinct temporal phases: neural induction phase (days 0-7), neural progenitor expansion phase (days 7-14), and OPC differentiation phase (days 14-28), with specific growth factor combinations applied to each phase to achieve successful human OPC generation
2Loss of information
If the role of Olig2 transcription in human OPC specification is investigated using novel methods, then understanding of human neural development is improved, but the investigation complexity increases compared to established mouse models
Solution Approach 1:
The invention uses Olig2 as a molecular intermediary marker to track and identify OPC specification in human neural development. By monitoring Olig2 expression levels and timing during the differentiated culture, the method simplifies the investigation of OPC specification mechanisms without requiring complex genetic manipulation
Solution Approach 2:
The invention creates an in vitro model that copies key aspects of human neural development and OPC specification, allowing researchers to study Olig2 transcription roles in a controlled setting that mirrors in vivo conditions without the complexity of animal models
3Manufacturing precision
If human OPCs are generated with high purity and synchronous differentiation, then the quality of myelin-producing cells is improved, but the differentiation time and process control requirements increase
Solution Approach 1:
The invention applies periodic changes in growth factor concentrations and combinations at specific time intervals during differentiation. The protocol uses staged addition and removal of growth factors (FGF2, EGF, BDNF, GDNF) at defined time points to synchronize OPC differentiation and achieve high purity populations within a controlled 4-week period
Data Source
AI summary
A method of differentiating embryonic stem cells into oligodendroglial precursor cells and oligodendroglial cells by culturing a population of cells comprising a majority of cells that are characterized by a neural tube-like rosette morphology and are Pax6+/Sox1+ into a population of cells that are PDGFRα+.